Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-HTP in Spinal Cord Injuries
NCT04520178Phase 3Active, not recruiting
- Sponsor
- University of Alberta
- Start
- Jul 2020
- Primary completion
- May 2026
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of 5-hydroxytryptophan in spinal cord injury (SCI), sponsored by University of Alberta. Started Jul 2020; status: active, not recruiting.
02
Drugs
5-hydroxytryptophan
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04520178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520178.